TNF antibody new drug is expected to help NASH cell therapy
TNF antibody new drug is expected to help NASH cell therapy
April 12, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Promethera Biosciences, a pharmaceutical company developing hepatocyte therapy, today announced the acquisition of the Swiss biopharmaceutical company Baliopharm AG. The acquisition complements Promethera's drug pipeline and adds an antibody candidate specifically binding to Tumor Necrosis Factor Receptor 1 (TNF-R1). This new treatment strategy, combined with Promethera's unique hepatocyte therapy, provides a better treatment option for patients with nonalcoholic steatohepatitis (NASH) and other potentially severe liver diseases.
Promethera is a leader in hepatocellular medicine, and its leading clinical project is derived from its patented cell technology platform, HepaStem, which is designed to benefit from its immunomodulatory and anti-fibrotic properties. In addition to cell-based drug pipelines, the company has also developed antibody technology to complement and enrich treatment options.
Baliopharm focuses on the development of novel antibody therapies for the treatment of autoimmune diseases and cancers such as rheumatoid arthritis, Crohn's disease, psoriasis and multiple sclerosis. Baliopharm's antibody line consists of two selective TNF-R1 antagonists, Atrosab and Atrosimab, and an anti-CD20/CD95 bispecific antibody, Novotar.
Since the TNF-α pathway and TNF-R1 are involved in many inflammatory diseases, including chronic liver disease leading to fibrosis, therapeutic antibodies are valuable as a single therapy or in combination with Promethera's cell therapy technology HepaStem. Strategy. Through this acquisition, Promethera acquired all of Baliopharm's antibody development projects, specifically the creation of a unique next-generation selective TNF-R1 inhibitor, including the novel antibody candidate Atrosimab.
â–² Baliopharm AG R & D pipeline (Source: Baliopharm AG official website)
“The acquisition of Baliopharm adds a very promising antibody asset to our cell line, diversifying NASH treatment strategies through our proprietary combination therapy options. As cell therapy HepaStem develops rapidly into clinical trials in this indication, The complementary and potentially synergistic approach represented by Atrosimab strengthens our product portfolio and is extremely valuable and unique from an intellectual and scientific perspective,†said Dr. John Tchelingerian, President and CEO of Promethera: “ With today's acquisition, Promethera reaffirms its commitment and further realizes its vision to become a leading drug development organization in the field of severe liver disease using cell-based and bio-driven methods."
Dr. Andreas Herrmann, CEO of Baliopharm, commented: "Today's statement proves that strong science is the basis for our next-generation anti-TNF-R1 development project using the new antibody Atrosimab. Promethera has the ability to promote the development of Atrosimab and explore unique combinatorial strategies. Provide better treatment options for NASH patients in the future."
We expect this acquisition to develop more new therapies for the treatment of a variety of severe liver diseases including non-alcoholic steatohepatitis.
Reference materials:
[1] Promethera Biosciences Acquires Baliopharm AG to Strengthen its TherapeuticStrategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidate
[2] Promethera Biosciences official website
Dried Shiitake Mushroom,Dehydrated Mushroom Dice,Shiitake Mushroom Powder,Dried Shiitake Mushroom Cubes, Cheap Dried Shiitake Mushroom
Jiangsu Tiankang Food Co., Ltd. , https://www.tiankangfood.com